Hugh A. Sampson

Dean, Translational Biomedical Sciences at Icahn School of Medicine at Mount Sinai

Hugh A. Sampson

Hugh A. Sampson

Dean, Translational Biomedical Sciences at Icahn School of Medicine at Mount Sinai

Biography

Hugh A. SampsonChief Scientific Officer

Hugh A. Sampson, M.D. serves as Chief Scientific Officer and is a member of both the Executive Committee and the Company’s Scientific Advisory Board, responsible for leading global scientific efforts, overseeing DBV’s research team, researching potential new applications of investigational Viaskin® for the treatment of food allergies and autoimmune disorders, and supporting the Company’s clinical development teams. Dr. Sampson is also the Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai and Director Emeritus of the Jaffe Food Allergy Institute. He continues to direct his NIH-funded translational research activities and to see patients in clinical practice. Dr. Sampson is a member of the National Academy of Medicine, past chair of the Section on Allergy & Immunology of the American Academy of Pediatrics and the past-president of the American Academy of Allergy, Asthma and Immunology.

Dr. Sampson received his M.D. from the State University of New York at Buffalo School of Medicine and his allergy/immunology fellowship at Duke University.

Overview
Career Highlights

The American Academy of Allergy, Asthma and Immunology

RelSci Relationships

1394

Number of Boards

3

Birthday

1949

Age

71

Contact Data
Trying to get in touch with Hugh A. Sampson? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Hugh A. Sampson likely has professional access to. A relationship does not necessarily indicate a personal connection.

Executive Vice President & Chief Operating Officer at Icahn School of Medicine at Mount Sinai

Relationship likelihood: Strong

Executive Vice President, General Counsel at The Mount Sinai Hospital

Relationship likelihood: Strong

Former Vice Chairman at The Mount Sinai Medical Center, Inc.

Relationship likelihood: Strong

Former Senior Vice Chairman at The Mount Sinai Hospital

Relationship likelihood: Strong

Anne & Joel Ehrenkranz Dean at Icahn School of Medicine at Mount Sinai

Relationship likelihood: Strong

Executive Vice President & Chief Information Officer at St. Luke's-Roosevelt Hospital Center

Relationship likelihood: Strong

President & Chief Executive Officer at Loews Corp.

Relationship likelihood: Strong

Director, Center for Multicultural & Community Affairs at Icahn School of Medicine at Mount Sinai

Relationship likelihood: Strong

Co-Founder at DBV Technologies

Relationship likelihood: Strong

Manager at SCP Benhamou Vannerom

Relationship likelihood: Strong

Paths to Hugh A. Sampson
Potential Connections via
Relationship Science
You
Hugh A. Sampson
Dean, Translational Biomedical Sciences at Icahn School of Medicine at Mount Sinai
Education

The University at Albany, known officially as University at Albany, State University of New York, is an internationally recognized public research institution with campuses in Albany, Guilderland, and East Greenbush, New York, United States. The oldest university campus of the State University of New York (SUNY) system, founded in 1844, it carries out a broad mission of undergraduate and graduate education, research, and service, and has grown to be a flagship institution of New York. The University has three campuses: the Uptown Campus in Albany and Guilderland's McKownville neighborhood, the Downtown Campus in Albany, and the East Campus in East Greenbush, just east of Albany.

Boards & Committees
Member, Scientific Advisory Board
Current

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Member, Scientific Advisory Board
Current
President, Board of Directors
Prior

THE ADVANCEMENT AND PRACTICE OF ALLERGY AND IMMUNOLOGY THROUGH MEETINGS, EDUCATION, AND BY PROMOTING AND STIMULATING RESEARCH AND STUDY FOR OPTIMAL PATIENT CARE.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$1 - $499
2013

THE ADVANCEMENT AND PRACTICE OF ALLERGY AND IMMUNOLOGY THROUGH MEETINGS, EDUCATION, AND BY PROMOTING AND STIMULATING RESEARCH AND STUDY FOR OPTIMAL PATIENT CARE.

$1,000 - $2,499
2005

THE ADVANCEMENT AND PRACTICE OF ALLERGY AND IMMUNOLOGY THROUGH MEETINGS, EDUCATION, AND BY PROMOTING AND STIMULATING RESEARCH AND STUDY FOR OPTIMAL PATIENT CARE.

Up to $499
2004

THE ADVANCEMENT AND PRACTICE OF ALLERGY AND IMMUNOLOGY THROUGH MEETINGS, EDUCATION, AND BY PROMOTING AND STIMULATING RESEARCH AND STUDY FOR OPTIMAL PATIENT CARE.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Hugh A. Sampson. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Hugh A. Sampson's profile does not indicate a business or promotional relationship of any kind between RelSci and Hugh A. Sampson.